Aurobindo Pharma's step-down subsidiary bags USFDA Approval for Pemetrexed for Injection; stock adds ~1%

26 May 2022 , 12:17 PM

Aurobindo Pharma Limited announced that its wholly-owned subsidiary company, Eugia Pharma Specialties Limited, has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pemetrexed for Injection, 100 mg, 500mg, and 1000mg.

Pemetrexed for Injection USP, 100 mg/vial and 500 mg/vial, Single-Dose Vials, to be bioequivalent and therapeutically equivalent to the RLD, Alimta for Injection, 100 mg/vial and 500 mg/vial of Eli Lilly. The product is being launched immediately. The approved product has an estimated market size of US$ 1272 million for the twelve months ending March 2022, according to IQVIA.

This is the 139th ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer).

Aurobindo Pharma is currently trading at Rs529.35 up by Rs6.2 or 1.19% from its previous closing of Rs523.15 on the BSE. The scrip opened at Rs531.15 and has touched intraday high and low of Rs531.30 and Rs518.30 respectively.